Nuveen LLC Buys Shares of 48,601 ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Nuveen LLC acquired 48,601 shares of ANI Pharmaceuticals, valued at approximately $3,254,000, increasing its ownership to 0.22% of the company.
• Several institutional investors, including Millennium Management LLC and GAMMA Investing LLC, significantly increased their stakes in ANI Pharmaceuticals, contributing to a total of 76.05% of the company's stock held by institutional investors.
• ANI Pharmaceuticals reported impressive quarterly earnings, with an EPS of $1.80, surpassing estimates, and revenue of $211.37 million, a year-over-year increase of 53.2%.

Nuveen LLC bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the first quarter, according to its most recent filing with the SEC. The firm bought 48,601 shares of the specialty pharmaceutical company's stock, valued at approximately $3,254,000. Nuveen LLC owned approximately 0.22% of ANI Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of ANIP. National Bank of Canada FI purchased a new position in ANI Pharmaceuticals during the 1st quarter worth approximately $79,000. GAMMA Investing LLC raised its position in ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after buying an additional 881 shares during the last quarter. Rafferty Asset Management LLC purchased a new position in ANI Pharmaceuticals during the 4th quarter worth approximately $200,000. Bridgefront Capital LLC purchased a new position in ANI Pharmaceuticals during the 4th quarter worth approximately $204,000. Finally, Mesirow Financial Investment Management Inc. purchased a new position in ANI Pharmaceuticals during the 1st quarter worth approximately $206,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP traded up $0.97 on Friday, hitting $93.50. The company had a trading volume of 283,240 shares, compared to its average volume of 749,580. The company has a market capitalization of $2.03 billion, a PE ratio of 18.19 and a beta of 0.63. The company's fifty day moving average price is $73.39 and its 200-day moving average price is $67.12. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $93.72.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. The company had revenue of $211.37 million during the quarter, compared to analyst estimates of $187.18 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm's revenue was up 53.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.02 EPS. As a group, analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. HC Wainwright reissued a "buy" rating and set a $93.00 price target (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a report on Monday, August 11th. Piper Sandler reaffirmed an "overweight" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Finally, Zacks Research raised shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 21st. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $84.75.

Insider Activity at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,763 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $91.10, for a total transaction of $160,609.30. Following the transaction, the senior vice president owned 62,896 shares of the company's stock, valued at approximately $5,729,825.60. The trade was a 2.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Matthew J. Leonard sold 2,528 shares of the business's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $90.62, for a total transaction of $229,087.36. Following the transaction, the director directly owned 6,864 shares in the company, valued at approximately $622,015.68. The trade was a 26.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 405,538 shares of company stock worth $35,690,131 over the last 90 days. Corporate insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.